Frontera's APEX Technology & Manufacturing Platform is an innovative adeno-associated virus (AAV) gene expression system. It includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data, making it possible to develop novel gene therapy products with quicker speed-to-market and lower cost.
- World-class execution - leveraging fully integrated teams - across disease biology, gene therapy vector design, translational sciences, in-house GMP manufacturing and clinical research.
- State-of-the-art GMP facilities with up to 2000L scale.
- World-class and proven team in gene therapy R&D, having been in leading roles or as founders for some of the most successful and innovative gene therapy and gene editing products and companies.
- Early access to clinical data made possible by Frontera's unique scientific model.
Pipeline
Product development in gene therapy has historically focused on a limited number of rare monogenic disorders. The possibilities for gene therapy, however, are vastly greater. Frontera is realizing this potential with a pipeline that spans across not only orphan diseases, but also in larger patient markets – including Ophthalmology, Hematology, Neuromuscular and Metabolic Diseases.
World-Class R&D Team
Frontera's elite R&D team is made up of founders and scientific advisors from some of the most successful gene therapy development organizations around the world, bringing together the most advanced thinking in gene therapy, genetics, and biologics manufacturing.
Scientific Advisory Board
Philip Reilly, Ph.D.
Robert Kotin, Ph.D.
Fraser Wright, Ph.D.
George Church, Ph.D.
Jean Bennett, M.D., Ph.D.
Mark Kay, M.D., Ph.D.
Xandra Breakefield, Ph.D.
Founders
Yong Dai, Ph.D.
Founder & CEO
Philip Reilly, Ph.D.
Co-Founder & Science Advisory Board Chair
Robert Kotin, Ph.D.
Co-Founder & SAB Member
Xinyan Li, Ph.D.
Co-Founder & President
Board of Directors
Wei Li, Ph.D.
Chairman, Founding Partner of Creacion Ventures
Carl Gordon, Ph.D.
Founding Managing Director of OrbiMed Advisors
David Wang, Ph.D.
Managing Partner of OrbiMed Advisors
Ching Zhu, Ph.D.
Founding Partner of Creacion Ventures
Yong Dai, Ph.D.
Founder & CEO
Xinyan Li, Ph.D.
Co-Founder & President
Yanling Cao
Founding Partner of Boyu Capital
Jiang Han
Managing Director of Sequoia Capital
Mangement Team
The Frontera leadership team's experience spans from principal roles in global pharmaceutical companies to launching innovative biotech’s. The teams' expertise includes early research and development of gene therapy products and biologics, chemistry, manufacturing and Controls (CMC), clinical trial design and management, business development, registration and commercialization.
Yong Dai, Ph.D.
Founder & CEO
Xinyan Li, Ph.D.
Co-Founder & President
Stephen Lau
Chief Business Officer
Dean Falb, Ph.D.
Chief Scientific Officer
Shawn Harriman, Ph.D.
Chief Development Officer
Baochuan Huang
SVP of Manufacturing
Robert Lu, Ph.D.
VP of Technical Operations
Allison Jia
VP of Finance
Investors
Recent News
Coming soon...